NORPLAT-S Tablet

ក្រុមហ៊ុនផលិតឱសថ:

 

Getz Pharma(Pvt.) Limited, Pakistan.

ក្រុមហ៊ុនចែកចាយឱសថនៅប្រទេសកម្ពុជា:

 

ALLIANCE PHARMA CAMBODGE

  • សារធាតុសកម្ម
  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
  • ហាមប្រើ
  • ផលរំខាន
  • អន្តរប្រតិកម្ម
  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
  • ការប្រុងប្រយ័ត្នជាពិសេស
  • សកម្មភាពឱសថ
  • បរិយាយប័ណ្ណឱសថ 
  • សារធាតុសកម្ម

    1. NORPLAT-S Tablets 75mg+75mg:

    Clopidogrel 75mg, Aspirin 75mg

    2. NORPLAT-S Tablets 75mg+150mg:

    Clopidogrel 75mg, Aspirin 150mg

  • ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់

    - For the reduction of thrombotic events in patients with recent myocardial infarction, recent stroke, or established peripheral arterial disease.

    - Prophylactically in patients at risk of thromboembolic disorders such as myocardial infarction, peripheral arterial disease and stroke.

    - For acute coronary syndrome (unstable angina-non-Q-wave MI).

    Dosage and Administration

    This tablet can be administered with or without food.

    The recommended dose is 1 tablet daily.

    This tablet has been administered for up to 1 year.

  • ហាមប្រើ

    In patients:

    - who have shown hypersensitivity to clopidogrel, aspirin or any component of the product.

    - with active gastro-duodenal ulcers,

    - with hypersensitivity to salicylates (bronchospasm, anaphylactic reactions),

    - with haemorrhagic disease,

    - with severe hepatic function impairment,

    - who are pregnant,

    - who are lactating.

  • ផលរំខាន

    Gastrointestinal disturbances: Diarrhea, abdominal pain, indigestion, nausea and heart burn.

    Dermatological reactions: Rash, pruritus.

    Nephritic ion reactions: Edema, urticaria, asthma.

    Following adverse effects were reported rarely:

    Increase bleeding tendency, gastrointestinal bleeding, gastric ulcers, severe neutropenia or agranulocytosis, thrombocytopenia, thrombotic thrombocytopenic purpura, aplastic anemia, membranous nephropathy with nephritic syndrome, loss of taste, acute arthritis.

  • អន្តរប្រតិកម្ម

    (See the package insert about details.)

    Anticoagulants, coumarin, heparin or thrombolytic agents

    NSAIDs

    Methotrexate

    Antidiabetic agents

    Uricosuric agents

    Antacids

    Warfarin

    Drugs metabolized by CYP450

  • ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន

    Contraindicated.

  • ការប្រុងប្រយ័ត្នជាពិសេស

    Clopidogrel:

    Renal Insufficiency: After repeated doses of 75mg clopidogrel per day, plasma levels of the main circulating metabolite were lower in patients with severe renal impairment (creatinine clearance 5 -15 mL/min) compared to subjects with moderate renal impairment (creatinine clearance 30-60mL/min) or healthy subjects. However the prolongation of bleeding time was similar. No dose adjustment is required in mild to moderate renal impaired patients.

    Full blood count should be performed before starting treatment with this medicine and every 2 weeks during the first 3 months of therapy. If clopidogrel is discontinued during this period, a full blood count should be performed within 2 weeks of stopping treatment.

    Aspirin should be used with caution in

    - children or teenagers with chickenpox, influenza or fever.

    - patients who are allergic to ibuprofen or other NSAID medicines.

    - patients with chronic or recurrent stomach or duodenal ulcers or digestive hemorrhages.

    - patients with severe renal disease.

    - patient suffering from allergic diseases like asthma or urticaria.

    - patients suffering from gout.

    Clopidogrel should be used with caution

    - in patients who may be at risk of increased bleeding from trauma, surgery, or other pathological conditions.

    - if a patient is to undergo elective surgery, consideration should be given to stopping clopidogrel 5 days before surgery.

    - in patient who have lesions with a propensity to bleed (such as ulcers). Drugs that might induce such lesions should be used in caution in patients taking clopidogrel.

    Hepatic Impaired Patients

    Renal Impaired Patients

    This medicine should be used with caution in such patients. (see the package insert about details.)

  • សកម្មភាពឱសថ

    Clopidogrel

    Clopidogrel is an inhibitor of platelet aggregation, that is, a drug that inhibits the ability of platelets to clump together as part of a blood clot.

    It appears to act by blocking the adenosine phosphate (ADP) receptors, which prevents fibrinogen binding to the receptor. This decreases the ability of platelet adhesion and aggregation. Clopidogrel is a prodrug and requires biotransformation to produce inhibition of platelet aggregation.

    Aspirin:

    Acetylsalicylic acid inhibits the activity of the enzyme cyclo-oxygenase and thus prostaglandins and thromboxane formation are decreased. By blocking thromboxane synthesis, acetylsalicylic acid inhibits rapidly the platelet aggregation; this action is irreversible. Acetylsalicylic acid may also inhibit formation of prostacyclin, a platelet aggregation inhibitor; this action is reversible.

*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។

ប្រភពព័ត៌មាន៖

- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp

- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp